Skip to content
MARKETS / NYSE / AMS
NYSE · SERVICES-MEDICAL LABORATORIES · SMALL CAP

American Shared Hospital Services AMS

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$28.1M
▼ 0.9% YoY
$-1.6M
▼ 171.0% YoY
$-4.5M
In brief

What this company does

The Company delivers radiation therapy through medical equipment leasing and direct patient services, its two reportable segments. The Company currently provides Gamma Knife services through its 81% indirect interest in GK Financing, LLC, a California limited liability company (“GKF”) to seven medical centers in eight states in the United States, and owns and operates two Gamma Knife units at stand-alone facilities in Lima, Peru and Guayaquil, Ecuador. The remaining 19% of GKF is owned by GKV Investments, Inc. (“GKV Investments”), a wholly-owned U.S. subsidiary of Elekta AG, a Swedish company (“Elekta”). The Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), ASHS-Mexico, S.A. de C.V. (“ASHS-Mexico”), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC (“RI PBRT”), ASHS-Bristol Radiation Therapy, LLC (“Bristol”), OR21, Inc. and MedLeader.com, Inc. (“MedLeader”).

Written from the business description in American Shared Hospital Services's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 28.1M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 28.1 · Net income -1.6
10.0M20.0M-2.5M-5.0M200920112013201520172019202120232025
Compound annual growth
+12.5%
+9.5%
+5.4%
+3.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +9.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−10 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -12.8% · Net -9.7%
5%10%15%-20%-40%200920112013201520172019202120232025
ROE
FY2025 · ROE -6.3%
5%-10%-20%-30%200920112013201520172019202120232025

Each USD of equity lost 6 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -4.5
4M8M-4M200920112013201520172019202120232025
Net buybacks $ Dividends $
FY2016 · Dividends — · Net buybacks 0.0
10000020000020092010201120122013201420152016

Total assetsUSD 55.5M
EquityUSD 24.0M
CashUSD 3.5M
Gross debtUSD 17.3M
Net debtUSD 13.8M
Current ratio0.76×

Net debt stands at 58% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.00.00.00.0−0.00.00.00.00.00.0−0.00.00.00.00.00.0
EBITDA $B··0.00.00.0−0.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B−0.0−0.00.00.00.0−0.00.00.0−0.00.00.00.00.00.00.00.00.0
Net income $B−0.00.00.00.00.0−0.00.00.00.00.0−0.0−0.0−0.00.00.00.0−0.0
Free cash flow $B−0.0−0.0−0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $−0.230.330.100.210.03−1.140.110.170.330.17−0.28−0.19−0.070.010.110.01−0.04
Dividend / sh $·················
Payout %·················
ROE %−6.39.12.86.41.0−31.22.64.28.54.5−7.3−4.6−1.60.22.50.3·
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.000.000.000.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 81 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 14 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityServices-Medical Laboratories
Listed onNYSE
Incorporated inCalifornia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image